INTRODUCTION
Since the first description of the creation of transgenic mice in the early 1980s, refinements of genetic engineering and animal modeling technologies have allowed for remarkable advances in biomedical research (16 (3, 17) . Subsequently, SOD models have been employed to study the pathogenesis of human motor neuron diseases such as amyotrophic lateral sclerosis (19) . Exacerbated brain injury has also been demonstrated to result from reduced antioxidant levels in apolipoprotein E-deficient mice in closed head injury models (12) . As (13) and may now be used to determine whether certain toxic effects are mediated by this family of molecules.
Mouse modeling technology and its application in toxicology are growing and evolving fields, and as such there will be challenges and problems ahead. These problems are already particularly evident in the use of genetically altered mice for hazard identification, as seen in current debates regarding &dquo;validation&dquo; of new models, proper usage of the models, how data are interpreted, and how data will be used for regulatory purposes (14) . However, the application of these animal models in mechanism-based toxicology to address specific hypotheses has already become well entrenched and will undoubtedly continue to grow.
